Drug intelligence / Profile preview

CS-0003

Development stage: Unknown
Lead developer: 32 Biosciences
Modality: Small Molecules

Overview

CS-0003 is a proprietary compound developed by 32 Biosciences (formerly Covira), a biotech company spun out of the University of Chicago. It is designed to prevent post-surgical infections by modulating bacterial virulence and the gut microbiome. The foundational science for CS-0003 was supported by NIH grants to the scientific co-founders at the University of Chicago and produced in partnership with The Pritzker School of Molecular Engineering.

Beyond the preview

Go deeper on CS-0003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-0003.

Explore the full profile